Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
95 results:

  • 1. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
    McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
    J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [A Case of Stage Ⅳc dMMR Transverse Colon cancer with Complete Response to Combination Therapy with Immune Checkpoint Inhibitor in Stage ⅣB Lung Adenocarcinoma].
    Kageyama C; Yoshimatsu K; Tanaka H; Higashida M; Ito Y; Okada T; Endo S; Fujiwara Y; Ueno T
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1114-1116. PubMed ID: 38035848
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic colorectal cancer on pembrolizumab: A Case Report.
    Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in colorectal cancer and Invasive Breast cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. GART Functions as a Novel Methyltransferase in the RUVBL1/β-Catenin Signaling Pathway to Promote Tumor Stemness in colorectal cancer.
    Tang C; Ke M; Yu X; Sun S; Luo X; Liu X; Zhou Y; Wang Z; Cui X; Gu C; Yang Y
    Adv Sci (Weinh); 2023 Sep; 10(25):e2301264. PubMed ID: 37439412
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.
    Sur D; Lungulescu C; Dumitrescu EA; Afrăsânie V; Spînu Ș; Lungulescu CV; Schmoll HJ
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):633-641. PubMed ID: 37127555
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. muc1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
    Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
    Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Genetic alterations shaping tumor response to anti-EGFR therapies.
    Vaquero J; Pavy A; Gonzalez-Sanchez E; Meredith M; Arbelaiz A; Fouassier L
    Drug Resist Updat; 2022 Sep; 64():100863. PubMed ID: 36063655
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
    Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-muc1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
    Ochsenreither S; Fiedler WM; Conte GD; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda E
    ESMO Open; 2022 Apr; 7(2):100447. PubMed ID: 35397434
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic colorectal cancer.
    Redman JM; Tsai YT; Weinberg BA; Donahue RN; Gandhy S; Gatti-Mays ME; Abdul Sater H; Bilusic M; Cordes LM; Steinberg SM; Marte JL; Jochems C; Kim SS; Marshall JL; McMahon S; Redmond E; Schlom J; Gulley JL; Strauss J
    Oncologist; 2022 Mar; 27(3):198-209. PubMed ID: 35274710
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Trifluridine/tipiracil in the treatment of gastric cancer.
    Fostea RM; Arkenau HT
    Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Smart delivery of epirubicin to cancer cells using aptamer-modified ferritin nanoparticles.
    Yazdian-Robati R; Bayat P; Dehestani S; Hashemi M; Taghdisi SM; Abnous K
    J Drug Target; 2022 Jun; 30(5):567-576. PubMed ID: 34991424
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Fluorescence-guided surgery in colorectal cancer; A review on clinical results and future perspectives.
    Galema HA; Meijer RPJ; Lauwerends LJ; Verhoef C; Burggraaf J; Vahrmeijer AL; Hutteman M; Keereweer S; Hilling DE
    Eur J Surg Oncol; 2022 Apr; 48(4):810-821. PubMed ID: 34657780
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. MSI testing : What's new? What should be considered?
    Rüschoff J; Baretton G; Bläker H; Dietmaier W; Dietel M; Hartmann A; Horn LC; Jöhrens K; Kirchner T; Knüchel R; Mayr D; Merkelbach-Bruse S; Schildhaus HU; Schirmacher P; Tiemann M; Tiemann K; Weichert W; Büttner R
    Pathologe; 2021 Nov; 42(Suppl 1):110-118. PubMed ID: 34477921
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Targeted SPION siderophore conjugate loaded with doxorubicin as a theranostic agent for imaging and treatment of colon carcinoma.
    Nosrati R; Abnous K; Alibolandi M; Mosafer J; Dehghani S; Taghdisi SM; Ramezani M
    Sci Rep; 2021 Jun; 11(1):13065. PubMed ID: 34158526
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.].
    Danesi R; Cremolini C; Ciccarone F; Lorusso D
    Recenti Prog Med; 2021 Jun; 112(6):444-453. PubMed ID: 34128936
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [MSI testing : What is new? What should be considered? German version].
    Rüschoff J; Baretton G; Bläker H; Dietmaier W; Dietel M; Hartmann A; Horn LC; Jöhrens K; Kirchner T; Knüchel R; Mayr D; Merkelbach-Bruse S; Schildhaus HU; Schirmacher P; Tiemann M; Tiemann K; Weichert W; Büttner R
    Pathologe; 2021 Jul; 42(4):414-423. PubMed ID: 34043067
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The ema assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
    Trullas A; Delgado J; Genazzani A; Mueller-Berghaus J; Migali C; Müller-Egert S; Zander H; Enzmann H; Pignatti F
    ESMO Open; 2021 Jun; 6(3):100145. PubMed ID: 33940347
    [TBL] [Abstract] [Full Text] [Related]  


    of 5.